<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02023242</url>
  </required_header>
  <id_info>
    <org_study_id>CP-12-001</org_study_id>
    <nct_id>NCT02023242</nct_id>
  </id_info>
  <brief_title>Comparing Effectiveness of the Hydrus Microstent (TM) to Two iStents to Lower IOP in Phakic Eyes</brief_title>
  <acronym>COMPARE</acronym>
  <official_title>A Prospective, Multicenter, Randomized Comparison of the Hydrus to the iStentÂ® for Lowering Intraocular Pressure in Primary Open Angle Glaucoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ivantis, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ivantis, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial compares two implantable devices intended to lower the pressure inside
      the eye of glaucoma patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multicenter, single-masked, randomized clinical trial comparing the
      Hydrus Microstent to two iStent implants for the reduction of intraocular pressure in phakic
      patients with a positive diagnosis of primary open angle glaucoma, pseudoexfoliative
      glaucoma, or pigmentary dispersion glaucoma. Post-operative follow-up visits will be
      conducted at regular intervals.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">January 2018</completion_date>
  <primary_completion_date type="Actual">August 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Unmedicated IOP &lt;/= 19 mmHg at 12 Months</measure>
    <time_frame>12 months</time_frame>
    <description>Percentage of subjects with IOP &lt;/= 19 mmHg and without the use of ocular hypotensive medications at 12 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Percentage of Subjects Who Are Not Using Ocular Hypotensive Medications at 12 and 24 Months</measure>
    <time_frame>12 &amp; 24 Months</time_frame>
    <description>The percentage of subjects who are not using ocular hypotensive medications at 12 and 24 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Medication Use at 12 and 24 Months</measure>
    <time_frame>12 &amp; 24 Months</time_frame>
    <description>The mean medication use at 12 and 24 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unmedicated IOP &lt;/= 19 mmHg at 24 Months</measure>
    <time_frame>24 Months</time_frame>
    <description>Percentage of subjects with IOP &lt;/= 19 mmHg and without the use of ocular hypotensive medications at 24 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unmedicated IOP &lt;/= 18 mmHg at 12 Months</measure>
    <time_frame>12 months</time_frame>
    <description>Percentage of subjects with IOP &lt;/= 18 mmHg and without the use of ocular hypotensive medications at 12 months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">152</enrollment>
  <condition>Primary Open Angle Glaucoma</condition>
  <condition>Pseudoexfoliative Glaucoma</condition>
  <condition>Pigmentary Glaucoma</condition>
  <arm_group>
    <arm_group_label>Hydrus Microstent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to the Hydrus Microstent .</description>
  </arm_group>
  <arm_group>
    <arm_group_label>iStent Trabecular Micro Bypass</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized to the iStent Trabecular Micro Bypass</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hydrus Microstent</intervention_name>
    <description>Device inserted into Schlemm's canal to enhance aqueous flow from the anterior chamber.</description>
    <arm_group_label>Hydrus Microstent</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>iStent Trabecular Micro Bypass</intervention_name>
    <description>Device inserted into Schlemm's canal to enhance aqueous flow from the anterior chamber.</description>
    <arm_group_label>iStent Trabecular Micro Bypass</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A diagnosis of primary open angle glaucoma (POAG), Pseudoexfoliative (PXG) glaucoma,
             or Pigmentary glaucoma (PG)

          -  A phakic lens with BCVA of 20/30 or better

        Exclusion Criteria:

          -  Forms of primary or secondary glaucoma not listed above

          -  Prior glaucoma surgery in the study eye
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>84 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julian Garcia Feijoo, Prof. Med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Madrid, Spain</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Contact Richard Hope at Ivantis</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>December 23, 2013</study_first_submitted>
  <study_first_submitted_qc>December 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 30, 2013</study_first_posted>
  <results_first_submitted>October 18, 2019</results_first_submitted>
  <results_first_submitted_qc>November 25, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">December 10, 2019</results_first_posted>
  <last_update_submitted>November 25, 2019</last_update_submitted>
  <last_update_submitted_qc>November 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Primary open angle glaucoma</keyword>
  <keyword>POAG</keyword>
  <keyword>Pseudoexfoliative glaucoma</keyword>
  <keyword>PXG</keyword>
  <keyword>Pigmentary glaucoma</keyword>
  <keyword>PG</keyword>
  <keyword>Hydrus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 7, 2012</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/42/NCT02023242/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were screened and enrolled at 12 investigational sites located outside of the United States</recruitment_details>
      <pre_assignment_details>152 patients were randomized</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Hydrus Microstent</title>
          <description>Subjects underwent 1 Hydrus implantation</description>
        </group>
        <group group_id="P2">
          <title>iStent Trabecular Micro Bypass</title>
          <description>Subjects underwent 2 iStents implantation</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
                <participants group_id="P2" count="77"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="72"/>
                <participants group_id="P2" count="75"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent-to-Treat (ITT) - All participants randomized and grouped according to their randomization assignment</population>
      <group_list>
        <group group_id="B1">
          <title>Hydrus Microstent</title>
          <description>Subjects underwent 1 Hydrus implantation</description>
        </group>
        <group group_id="B2">
          <title>iStent Trabecular Micro Bypass</title>
          <description>Subjects underwent 2 iStents implantation</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="75"/>
            <count group_id="B2" value="77"/>
            <count group_id="B3" value="152"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.5" spread="10.3"/>
                    <measurement group_id="B2" value="66.5" spread="9.5"/>
                    <measurement group_id="B3" value="67.0" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="86"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Caucasian/White European</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African Descent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native North American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic/Latino/Central &amp; So American Origin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Unmedicated IOP &lt;/= 19 mmHg at 12 Months</title>
        <description>Percentage of subjects with IOP &lt;/= 19 mmHg and without the use of ocular hypotensive medications at 12 months</description>
        <time_frame>12 months</time_frame>
        <population>Intent-to-Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Hydrus Microstent</title>
            <description>Subjects underwent 1 Hydrus implantation</description>
          </group>
          <group group_id="O2">
            <title>iStent Trabecular Micro Bypass</title>
            <description>Subjects underwent 2 iStents implantation</description>
          </group>
        </group_list>
        <measure>
          <title>Unmedicated IOP &lt;/= 19 mmHg at 12 Months</title>
          <description>Percentage of subjects with IOP &lt;/= 19 mmHg and without the use of ocular hypotensive medications at 12 months</description>
          <population>Intent-to-Treat (ITT)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.2"/>
                    <measurement group_id="O2" value="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Percentage of Subjects Who Are Not Using Ocular Hypotensive Medications at 12 and 24 Months</title>
        <description>The percentage of subjects who are not using ocular hypotensive medications at 12 and 24 months</description>
        <time_frame>12 &amp; 24 Months</time_frame>
        <population>Intent-to-Treat (ITT). Number of Participants Analyzed at 24 Months in the Hydrus Microstent arm are different than at 12 Months due to patients lost to follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>Hydrus Microstent</title>
            <description>Subjects underwent 1 Hydrus implantation</description>
          </group>
          <group group_id="O2">
            <title>iStent Trabecular Micro Bypass</title>
            <description>Subjects underwent 2 iStents implantation</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Subjects Who Are Not Using Ocular Hypotensive Medications at 12 and 24 Months</title>
          <description>The percentage of subjects who are not using ocular hypotensive medications at 12 and 24 months</description>
          <population>Intent-to-Treat (ITT). Number of Participants Analyzed at 24 Months in the Hydrus Microstent arm are different than at 12 Months due to patients lost to follow-up</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>12 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="73"/>
                    <count group_id="O2" value="75"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.6"/>
                    <measurement group_id="O2" value="24.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="75"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.0"/>
                    <measurement group_id="O2" value="18.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Medication Use at 12 and 24 Months</title>
        <description>The mean medication use at 12 and 24 months</description>
        <time_frame>12 &amp; 24 Months</time_frame>
        <population>Intent-to-Treat (ITT). Number of Participants Analyzed at 24 Months in the Hydrus Microstent arm are different than at 12 Months due to patients lost to follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>Hydrus Microstent</title>
            <description>Subjects underwent 1 Hydrus implantation</description>
          </group>
          <group group_id="O2">
            <title>iStent Trabecular Micro Bypass</title>
            <description>Subjects underwent 2 iStents implantation</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Medication Use at 12 and 24 Months</title>
          <description>The mean medication use at 12 and 24 months</description>
          <population>Intent-to-Treat (ITT). Number of Participants Analyzed at 24 Months in the Hydrus Microstent arm are different than at 12 Months due to patients lost to follow-up</population>
          <units>number of medications</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>12 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="73"/>
                    <count group_id="O2" value="75"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.99" spread="1.07"/>
                    <measurement group_id="O2" value="1.69" spread="1.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="75"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.23" spread="1.15"/>
                    <measurement group_id="O2" value="1.91" spread="1.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Unmedicated IOP &lt;/= 19 mmHg at 24 Months</title>
        <description>Percentage of subjects with IOP &lt;/= 19 mmHg and without the use of ocular hypotensive medications at 24 months</description>
        <time_frame>24 Months</time_frame>
        <population>Intent-to-Treat (ITT). Number of Participants Analyzed at 24Months in the Hydrus Microstent arm are different than at 12 Months due to patients lost to follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>Hydrus Microstent</title>
            <description>Subjects underwent 1 Hydrus implantation</description>
          </group>
          <group group_id="O2">
            <title>iStent Trabecular Micro Bypass</title>
            <description>Subjects underwent 2 iStents implantation</description>
          </group>
        </group_list>
        <measure>
          <title>Unmedicated IOP &lt;/= 19 mmHg at 24 Months</title>
          <description>Percentage of subjects with IOP &lt;/= 19 mmHg and without the use of ocular hypotensive medications at 24 months</description>
          <population>Intent-to-Treat (ITT). Number of Participants Analyzed at 24Months in the Hydrus Microstent arm are different than at 12 Months due to patients lost to follow-up</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.9"/>
                    <measurement group_id="O2" value="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Unmedicated IOP &lt;/= 18 mmHg at 12 Months</title>
        <description>Percentage of subjects with IOP &lt;/= 18 mmHg and without the use of ocular hypotensive medications at 12 months</description>
        <time_frame>12 months</time_frame>
        <population>Intent-to-Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Hydrus Microstent</title>
            <description>Subjects underwent 1 Hydrus implantation</description>
          </group>
          <group group_id="O2">
            <title>iStent Trabecular Micro Bypass</title>
            <description>Subjects underwent 2 iStents implantation</description>
          </group>
        </group_list>
        <measure>
          <title>Unmedicated IOP &lt;/= 18 mmHg at 12 Months</title>
          <description>Percentage of subjects with IOP &lt;/= 18 mmHg and without the use of ocular hypotensive medications at 12 months</description>
          <population>Intent-to-Treat (ITT)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.1"/>
                    <measurement group_id="O2" value="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 Months</time_frame>
      <desc>An adverse event is any untoward medical occurrence, unintended disease or injury, or untoward clinical signs in subjects, users or other persons, whether or not related to the investigational medical device. All subjects who have been exposed to the study treatment were evaluated for adverse events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Hydrus Microstent</title>
          <description>Subjects underwent 1 Hydrus implantation</description>
        </group>
        <group group_id="E2">
          <title>iStent Trabecular Micro Bypass</title>
          <description>Subjects underwent 2 iStents implantation</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>BCVA loss &gt;/= 2 lines ETDRS &gt;/= 3 months</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>IOP Increase</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>IOP increase (&gt;=10 mmHg than BL &gt;= 1M)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Inflammation lasting &gt;1M</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Proliferative Diabetic Retinopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Uncontrolled Glaucoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Wet Age Related Macular Degeneration</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>BCVA loss &gt;= 2 lines ETDRS &gt;= 3M (Post-Operative)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="75"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Device Obstruction (Post-Operative)</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="75"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>PAS with Device Obstruction (Post-Operative)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="75"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>PAS without Device Obstruction (Post-Operative)</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="75"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Device Malposition (Intraoperative)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>&quot;If the Clinical Investigation is multi-centered, any publication based on the results obtained at the Investigation Site (or a group of sites) shall not be made before the first multi-center publication.&quot;</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Richard Hope</name_or_title>
      <organization>Ivantis, Inc.</organization>
      <phone>949-333-1310</phone>
      <email>rhope@ivantisinc.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

